Orexin, also known as hypocretin, is a brain hormone that helps regulate sleep. A deficiency of this hormone can cause a person to develop type 1 narcolepsy. Type 1 narcolepsy, formerly known as ...

周三，Leerink Partners对Centessa Pharmaceuticals (NASDAQ:CNTA)的股票表示信心，将其目标价从22美元上调至24美元，同时维持"优于大市"评级。该公司更新后的模型反映了对Centessa产品管线的更为乐观的看法，特别是ORX750项目。

AstraZeneca has ended work on an opioid use disorder (OUD) drug after the orexin 1 receptor antagonist demonstrated a ...

Orexin antagonists, meanwhile – such as Eisai's Dayvigo (lemborexant), Merck & Co's Belsomra (suvorexant) and Idorsia's recently filed daridorexant – have proved effective as treatments for ...

Idorsia has become the first drugmaker in the EU to claim approval for a drug for chronic insomnia in the dual orexin receptor antagonist class, ahead of rival drugs from Merck & Co and Eisai.

Alkermes has shifted from royalty-based revenues to proprietary product sales, driven by strong growth in Lybalvi, Vivitrol, ...

The European Patent Office will issue a formal grant for TheraCryf's drug, the 'Ox-1' receptor anatagonist, on December 18. The drug was developed by British biotech firm Chronos Therapeutics Ltd, ...

Leerink Partners analyst David Risinger has reiterated their bullish stance on CNTA stock, giving a Buy rating yesterday. David Risinger has ...

NLS Pharmaceutics (NLSP) provided insights into the preclinical program evaluating its dual orexin receptor agonist platform. AEX-41 and ...

ORX750 was designed using Nxera technology to directly target the underlying pathophysiology of orexin neuron loss in NT1, ...